NZ567095A - Anti-infective agent and use thereof - Google Patents

Anti-infective agent and use thereof

Info

Publication number
NZ567095A
NZ567095A NZ567095A NZ56709509A NZ567095A NZ 567095 A NZ567095 A NZ 567095A NZ 567095 A NZ567095 A NZ 567095A NZ 56709509 A NZ56709509 A NZ 56709509A NZ 567095 A NZ567095 A NZ 567095A
Authority
NZ
New Zealand
Prior art keywords
infective agent
medicament
infection
mdp
plague
Prior art date
Application number
NZ567095A
Inventor
Frank B Gelder
Gillian A Webster
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Priority to NZ567095A priority Critical patent/NZ567095A/en
Publication of NZ567095A publication Critical patent/NZ567095A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is the use of a muramyl dipeptide (MDP)/DNA-microparticle for the manufacture of a medicament for the prophylactic or therapeutic treatment of an infection caused by a virus and/or a bacterium in a subject in need thereof. The medicament can induce a Th1-type immune response and the infection to be treated can be influenza, plague or tuberculosis.
NZ567095A 2009-04-01 2009-04-01 Anti-infective agent and use thereof NZ567095A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ567095A NZ567095A (en) 2009-04-01 2009-04-01 Anti-infective agent and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ567095A NZ567095A (en) 2009-04-01 2009-04-01 Anti-infective agent and use thereof

Publications (1)

Publication Number Publication Date
NZ567095A true NZ567095A (en) 2012-11-30

Family

ID=47221621

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ567095A NZ567095A (en) 2009-04-01 2009-04-01 Anti-infective agent and use thereof

Country Status (1)

Country Link
NZ (1) NZ567095A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease

Similar Documents

Publication Publication Date Title
HRP20180237T4 (en) Methods for treating hcv
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MX2013005727A (en) Oligosaccharide composition for treating acute respiratory tract infections.
NZ597059A (en) Inhibitors of influenza viruses replication
MX2013004817A (en) Inflammatory disease.
NZ624059A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
AU2010203451A8 (en) Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
MX338764B (en) Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
PH12015500361B1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
MX2011011109A (en) Oral formulations of bendamustine.
MX2013003060A (en) Combination therapy for treating hcv infection.
SG179082A1 (en) Method for the preparation of an influenza virus
MX2013003245A (en) Bvdv vaccine.
NZ601890A (en) Treatment or prevention of infection
MY172788A (en) Influenza vaccines
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
NZ567095A (en) Anti-infective agent and use thereof
WO2013173256A3 (en) New and improved influenza vaccines
BR112012017870A2 (en) enterococcal cell wall components and uses thereof
TN2013000134A1 (en) Combination therapy for treating hcv infection
UA90646C2 (en) treatment OF often RECCURENT chronic herpetic infection caused by herpes virus of simple I and II type
UA49146U (en) preparation for oral use

Legal Events

Date Code Title Description
AVOD Application void
S37A Application for proceedings under section 37 (restoration of application where complete specification not accepted)
S37R Proceedings under section 37 (restoration of application where complete specification not accepted): application restored
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 APR 2016 BY SHELSTON IP

Effective date: 20130308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2017 BY SHELSTON IP PTY LTD

Effective date: 20160129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2018 BY SHELSTON IP PTY LTD

Effective date: 20170327

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2019 BY SHELSTON IP PTY LTD

Effective date: 20180305

LAPS Patent lapsed